Look Beyond
the Limits

in Ophthalmology

Join us as we enter the new era of vision.

Hero Image. Woman Smiling

Look Beyond
the Limits

in Ophthalmology

Join us as we enter the new era of vision.

Hero Image. Woman Smiling

Here at Genentech, we are transforming ophthalmology
… and opening up The Window to Change.

Doctor looking into microscope

Our Commitment to Ophthalmology 

Vision loss affects more than 250 million people worldwide, making it one of the leading public health issues in the world. Currently, visual impairment is expected to reach 43 million patients with DME and 29 million patients with nAMD by 2040. At Genentech, we are focused on tackling these problems from a new perspective. With the global retina community, we are changing how we approach medical innovation by exploring cutting-edge technology and pioneering new therapies. We are changing how patients experience their care, for the better, by looking beyond the therapy, developing integrated digital solutions that support patients and physicians every step of the way. Join us as we lead and help shape the future of ophthalmology, together.

Beaker representing a section for realities of retinal disease

Realities of 
Retinal Disease 

Focused on tackling the leading causes of vision loss to better meet patient needs

Microscope representing a section for the genentech commitment

The Genentech
Commitment

Considered the founder of the industry, Genentech has been delivering on the promise of biotechnology for more than 40 years

Hand representing a section for innovation through our pipeline

Innovation and 
Our Pipeline

Leading the industry with the strongest research and development pipeline

DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration.